BSX - רווח לפני ריבית, מסים ופחת bostonscientific.com

Steady revenue growth for Boston Scientific (BSX) amid an aging population offsets the risks of Asian electronics supply chain disruptions. The EBITDA_Co metric clearly demonstrates this trend, with the current value standing at 5991.65. Operating profit confirms the business's resilience, while the strategic vector has shifted toward acquiring startups and implementing innovative minimally invasive implants in cardiology.

Boston Scientific is optimizing costs by outsourcing component manufacturing and logistics to external partners. The EBITDA_Co metric captures the cash balance from these activities before interest and taxes. This metric allows for an assessment of the business's actual ability to act as a cash generator, excluding debt obligations. Stable growth confirms the efficiency of the operating model and capital resilience. By analyzing the EBITDA_Co chart, an investor identifies the true profitability trend.